To evaluate the efficacy and safety of Longxiang Pingchuan capsule in the treatment of cough variant asthma (phlegm-stasis syndrome) : a multicenter, randomized, double-blind simulated, positive d

Phase 4

• Conditions: Cough variant asthma

• Registration Number: ITMCTR2200006869
• Lead Sponsor: Dongzhimen Hospital Beijing University of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 March 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) Consistent with the diagnosis of cough variant asthma;

(2) Cough score =13;

(3) In line with the syndrome differentiation of phlegm and blood stasis;

(4) Aged 18-79 (including 18 and 79), both sexes;

(5) Voluntarily participate in the clinical trial with informed consent and signed informed consent.

Exclusion Criteria

(1) Cough caused by other causes, Such as the common cold, chronic pharyngitis, upper airway cough syndrome, postnasal drip syndrome, acidophilic granulocyte sexual bronchitis, gastroesophageal reflux cough asthma, allergic cough, typicality, heart on sex cough, ears source sex cough, congenital respiratory disease, foreign bodies, suction, specific pathogens causing respiratory tract infection, drug induced cough, etc.;

(2) Have used inhaled glucocorticoids (ICS) and systemic sex hormones in the past week; Have used leukotriene modulators, ß2 receptor agonists, theophylline, anticholinergic drugs, antihistamines, antiallergic drugs, methylsulfonast, and traditional Chinese medicine (including decoction, decoction pieces, formula granules and Chinese medicine) with anticough, phlegm and antiasthmatic effects in the past 3 days.

(3) Gastrointestinal discomfort symptoms such as diarrhea, epigastric discomfort or noise;

(4) and severe heart, brain, liver, kidney, respiratory system and blood system and other major organs or serious diseases, such as lung cancer, pneumonia, chronic obstructive pulmonary disease and bronchial asthma (CVA), acute or chronic tracheobronchitis, acidophilic granulocyte bronchitis and bronchiectasis, atelectasis, pulmonary emphysema, or clear lung diseases such as pulmonary edema;

(5) Liver function ALT and AST exceeded the upper limit of the normal reference value 1.5 times or Scr exceeded the upper limit of the normal reference value;

(6) Allergic to test drugs (including positive drugs) or their ingredients and excipients;

(7) pregnant or lactating women, planning to become pregnant, patients of childbearing age who are unable or unwilling to take adequate contraception during the trial period or their spouses are unwilling to take contraceptive measures;

(8) Suspected or confirmed history of alcohol dependence, drug abuse or drug use;

(9) having an intellectual or mental handicap;

(10) Participating in or currently participating in clinical trials of other drugs or medical devices within 3 months;

(11) The investigator did not consider it appropriate to participate in the clinical trial.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cough degree score change;

Secondary Outcome Measures

Name	Time	Method
Cough disappearance rate;LCQ;Cough disappearance time;VAS;